Ainos Licensing Deal with BioPhoenix Co., Ltd. Worth $10M
Ainos entered into a global exclusive license agreement with BioPhoenix for its VELDONA low-dose oral interferon alpha technology platform for Sjögren’s Disease and Thrombocytopenia. Ainos will receive an upfront fee of $600,000 and is eligible for up to $10.0 million in total fees if additional indications are licensed, plus 25% of net sublicensing revenue. BioPhoenix will assume all clinical and regulatory funding and execution for the licensed indications.
- Value
- $10M
- Counterparty
- BioPhoenix Co., Ltd.
- Term
- 20 years